Last reviewed · How we verify

NCT04942522

Application of Probiotic PS128 in Children With ASD

Status unknown Phase 1 Last updated 31 August 2022
What this trial tests

Phase 1 trial testing probiotics PS128 in Autism Spectrum Disorder in 80 participants. Status unknown.

Timeline
6 June 2021
Primary endpoint
6 June 2023
6 October 2023

Quick facts

Lead sponsorYan Hao
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment80
Start date6 June 2021
Primary completion6 June 2023
Estimated completion6 October 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Yan Hao — full company profile →

Who can join

Adults 2 to 5, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the role of probiotics PS128 in improving gastrointestinal dysfunction and core behavioral symptoms in children with ASD, and investigate the underlying etiological mechanisms of ASD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The endocannabinoidome-gut microbiome-brain axis as a novel therapeutic target for autism spectrum disorder.
    Campanale A, Siniscalco D, Di Marzo V. · · 2025 · cited 2× · PMID 40605060 · DOI 10.1186/s12929-025-01145-7

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04942522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing